Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease

Caffeine, the most widely consumed stimulant globally, is known for its effects on wakefulness and motor coordination. Regular caffeine consumption has been linked to a reduced risk of Parkinson's disease (PD), with the effect being dose-dependent. This has been supported by animal studies showing caffeine's neuroprotective effects against PD-like neurodegeneration. However, decaffeinated coffee does not offer the same benefits, indicating that caffeine itself plays a crucial role. While caffeine's protective effects against PD are well-documented, its impact on those already diagnosed with PD is less clear. A controlled trial found that caffeine did not improve symptoms in PD patients and even increased dyskinesia, suggesting it is not effective as a symptomatic therapy. However, a meta-analysis suggested that caffeine might slow disease progression in early PD patients, though the studies varied in their methods, limiting the findings' applicability. Caffeine may protect against PD by modifying the dopamine system in the brain, interacting with adenosine receptors that affect dopamine function. This interaction has been explored as a potential treatment for PD, with mixed results in studies examining caffeine's effects on dopamine transporters in the brain. Some studies found no change, while others noted decreased dopamine transporter binding in coffee-drinking PD patients. This study aimed to test whether caffeine improves dopamine function and motor skills in PD patients over time, using brain imaging techniques to investigate its effects.